BeyondSpring (NASDAQ:BYSI – Get Free Report) and Oramed Pharmaceuticals (NASDAQ:ORMP – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, analyst recommendations and institutional ownership.
Analyst Ratings
This is a summary of recent recommendations for BeyondSpring and Oramed Pharmaceuticals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BeyondSpring | 1 | 0 | 0 | 0 | 1.00 |
| Oramed Pharmaceuticals | 0 | 0 | 1 | 0 | 3.00 |
Risk and Volatility
BeyondSpring has a beta of -0.12, indicating that its stock price is 112% less volatile than the S&P 500. Comparatively, Oramed Pharmaceuticals has a beta of 1.31, indicating that its stock price is 31% more volatile than the S&P 500.
Earnings & Valuation
This table compares BeyondSpring and Oramed Pharmaceuticals”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BeyondSpring | $1.75 million | 13.63 | -$1.01 million | ($0.12) | -4.83 |
| Oramed Pharmaceuticals | $2.00 million | 81.85 | $64.05 million | $6.16 | 0.64 |
Oramed Pharmaceuticals has higher revenue and earnings than BeyondSpring. BeyondSpring is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares BeyondSpring and Oramed Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BeyondSpring | N/A | N/A | -42.62% |
| Oramed Pharmaceuticals | N/A | -7.57% | -6.58% |
Institutional and Insider Ownership
40.3% of BeyondSpring shares are owned by institutional investors. Comparatively, 12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. 29.3% of BeyondSpring shares are owned by company insiders. Comparatively, 20.8% of Oramed Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
Oramed Pharmaceuticals beats BeyondSpring on 9 of the 12 factors compared between the two stocks.
About BeyondSpring
BeyondSpring is a biopharmaceutical company focused on developing therapies for cancer and complications associated with cancer treatment. Its research and development activities center on oncology drug candidates and supportive-care treatments. The company’s lead candidate is plinabulin, a small-molecule drug being investigated for use in preventing chemotherapy-induced neutropenia, a potentially serious drop in infection-fighting white blood cells. BeyondSpring has also studied plinabulin for its potential anti-cancer effects, including in lung cancer.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company developing oral drug-delivery technologies. Its platform is designed to protect protein-based medicines as they pass through the digestive system and support their absorption, with the aim of delivering medicines by mouth that have traditionally been given by injection. The company’s research has focused on oral treatments for metabolic conditions, including ORMD-0801, an oral insulin candidate, and an oral GLP-1 candidate. These products are investigational; Oramed does not market them as approved treatments.
Receive News & Ratings for BeyondSpring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring and related companies with MarketBeat.com's FREE daily email newsletter.
